{"nctId":"NCT04211909","briefTitle":"Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection","startDateStruct":{"date":"2020-01-03","type":"ACTUAL"},"conditions":["Hepatitis C Virus Infection"],"count":87,"armGroups":[{"label":"SOF/VEL","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL"]},{"label":"SOF/VEL/VOX","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL/VOX"]}],"interventions":[{"name":"SOF/VEL","otherNames":["Epclusa®","GS-7977/GS-5816"]},{"name":"SOF/VEL/VOX","otherNames":["Vosevi ®","GS-7977/GS-5816/GS-9857"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Chronic HCV infected males and non-pregnant/non-lactating females\n* Treatment-naive or treatment-experienced individuals\n* Non-cirrhosis or compensated cirrhosis at screening\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) < Lower Limit of Quantification (LLOQ) 12 Weeks After Discontinuation of Study Treatment","description":"SVR12 was defined as HCV RNA \\< LLOQ (i.e., 15 IU/mL) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinued the Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR < LLOQ 4 Weeks After Discontinuation of Study Treatment","description":"SVR4 was defined as HCV RNA \\< LLOQ (i.e.15 IU/mL) 4 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"Virologic failure was defined as:\n\nOn-treatment virologic failure:\n\n* Breakthrough (HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ, while on treatment, confirmed with 2 consecutive values), or\n* Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n* Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment )\n\nVirologic relapse:\n\n• Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ on Treatment","description":"LLOQ was 15 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","spread":null},{"groupId":"OG001","value":"69.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.95","spread":"0.866"},{"groupId":"OG001","value":"6.48","spread":"0.354"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.78","spread":"0.857"},{"groupId":"OG001","value":"-5.19","spread":"0.545"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.81","spread":"0.866"},{"groupId":"OG001","value":"-5.33","spread":"0.354"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.79","spread":"0.867"},{"groupId":"OG001","value":"-5.33","spread":"0.354"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.79","spread":"0.867"},{"groupId":"OG001","value":"-5.33","spread":"0.354"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Alanine Aminotransferase (ALT) Normalization","description":"Number of participants with ALT normalization, defined as ALT \\> upper limit of normal (ULN) (ULN = 43 U/L) at baseline and ALT ≤ ULN, at each visit was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":54},"commonTop":["Headache","Nausea","Rash"]}}}